ArticleBMC health services research2025
Burden of disease of Alzheimer disease in Italy: a real-world data analysis.
Article in BMC health services research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer's Disease: an Italian RAND/UCLA consensus.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Feasibility of the tailored activity program to bridge hospital and community care for people living with dementia and behavioral disorders: The "Continu-A-Mente" project.BMC geriatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlzheimer Disease (AD) represents a growing global health concern with profound socioeconomic implications, with predictions indicating a potential 50% increase in AD cases in Italy over the next 30 years. Timely diagnosis remains challenging due to the slow progression of symptoms and limited accessibility to advanced diagnostic tools, yet it remains one of the few tools available to prevent and alter the clinical course of the disease. The aim of this study is to build a cost-of-illness model to estimate the number of AD patients managed by the National Health Service, analyzing their use of hospital care, and estimating the social costs through real-world data.
methodsThe analysis encompassed a multifaceted approach, combining real-world data analysis from different sources for the period 2014-2019. Health direct costs related to AD in Italy were estimated thanks to the Italian database of all hospital discharges and a Local Health Unit database (400,000 residents) collecting all information on resource consumption related to AD. The National Social Security System database was used to estimate social security costs (disability compensations) related to Attendance Allowance (AA) recognitions.
resultsIn Italy a prevalence of 413,715 AD patients was estimated, with annual health direct costs per patient equal to €3,779. Annual social security costs related to AA recognitions amounted to 240 million euros. Overall, the analysis estimated an annual total cost exceeding 1.8 billion euros.
conclusionsThis study provides a comprehensive exploration of the multifaceted burden of AD in Italy, shedding light on its economic dimensions. The results underscore the urgency of prioritizing AD on political agendas, especially in the face of the projected global surge in AD cases. The study advocates for proactive policy interventions and informed healthcare decision-making to address the complex challenges posed by AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.